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The hepatitis C virus (HCV) is an enveloped virus that is about 50–70 nm in diameter, has positive-
strand RNA, and belongs to the genus Hepacivirus and the family Flaviridae. The detection and
quantiﬁcation of the core antigen, HCV nucleocapsid protein, has been successful in many trials and
is considered a marker of viral replication since it presents a sequence of highly conserved amino acids,
giving it high sensitivity and speciﬁcity. The E2 protein is an envelope glycoprotein of HCV with 11
glycosylation sites; most of these are well-conserved, making it a target antigen. The aim of this study is
to develop high-sensitivity, low-cost diagnostic methods for HCV, which could be used for serological
screening. The genomic regions encoding the core (part 136 aa) and E2 proteins of HCV were expressed
in Escherichia coli Rosetta strain, cloned in expression vector pET-42a, and induced with 0.4 mmol L1
IPTG, producing recombinant proteins that were fused to glutathione S-transferase (GST) protein,
which was then puriﬁed by afﬁnity chromatography. The immunoreactivity was assessed by Western
blot, Slot Blot, and developed and improved diagnostic methods (capture, indirect, and immunoblotting
enzyme-linked immunosorbent assay (ELISA)). After applying the results to the formulas for determin-
ing the quality parameters, obtained for immunoblotting method 100% sensitivity and speciﬁcity and
for ELISA 100% sensitivity and 87.5% speciﬁcity. The methods developed were more sensitive and
speciﬁc using the mixture of the recombinant proteins fused to GST (coreþE2).
& 2012 Elsevier B.V. All rights reserved.1. Introduction
The hepatitis C virus (HCV) is the main etiologic agent of
non-A/non-B hepatitis and infects approximately 170 million people
on the planet, which corresponds to 3% of the world population,
making hepatitis C a major cause of chronic liver disease worldwide
[1–4].
It is an enveloped virus that is about 50–70 nm in diameter,
has positive-strand RNA, and belongs to the genus Hepacivirus and
the family Flaviridae [5–7].
Its genome consists of a single positive strand of RNA of
approximately 9500 nucleotides and exhibits signiﬁcant genetic
variability, as a result of spontaneous mutations that occur during
viral replication [8]. The 50 and 30 UTR regions ﬂank a single
coding sequence known as the Open Reading Frame (ORF) [8]; it
encodes a precursor polyprotein of approximately 3010 aminoll rights reserved.
ax: þ55 16 3332 0486.
sta).acid residues, which is cleaved via the signaling mechanisms of
host and viral proteases, generating about 10 different structural
(core, E1, and E2) and nonstructural (NS2, NS3A, NS3B, NS4A,
NS4B, NS5A, and NS5B) proteins in addition to p7 protein [9–11].
They are all essential for infectivity and have different functions
[12,13].
HCV is the leading cause of chronic liver disease. There is still
no vaccine for HCV. The only currently effective treatment takes
48 weeks and combines interferon-alpha with ribavirin, but the
overall success rate is less than 50% depending on the viral
genotype [14]. The mortality rate from HCV in this decade is
expected to be double that of the last decade and to potentially
surpass the mortalities caused by HIV [4].
The HCV core antigen has been successfully detected and
quantiﬁed in many tests, exhibiting high sensitivity and antige-
nicity [15–18].
The E2 protein has 11 glycosylation sites, and most of them are
well conserved. It is, thus, a good target for the development of
antiviral molecules and also a target antigen [19]. It is being
considered as a major candidate for a vaccine against HCV since
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observed [20,21].
Many diagnostic tests have been developed since the isolation
of the complementary DNA of the hepatitis C virus (HCV) in
1989 [5]. Our aim was also to develop diagnostic methods for
HCV using the recombinant core and E2 proteins together, these
being of high sensitivity and low cost, which can be used for
serological screening. They are more appropriate for circumstances
in Brazil, where using national technology they can reduce the
costs of imported reagents and be standardized for viruses circu-
lating in Brazil.2. Material and methods
2.1. Trials with viral RNA
The detection of viral RNA was performed using the qualitative
test AMPLICORs Hepatitis C Virus Test version 2.0 (Roche Molecular
Systems, Branchburg, NJ, USA). This material was genotyped using
the commercial method INNO-LiPA HCV II (Innogeneticss, Bel-
gium), following the manufacturer’s instructions. To enhance the
isolation, concentration, and yield of HCV RNA, 1 mL of the
genotyped material and 50 mL of Bead Suspend from the kit
VERSANTs HCV RNA 3.0 Assay (bDNA) (Siemenss, Berlin, Ger-
many) were added to microtubes (DNase and RNase free) and then
stirred in a vortex for 10 s and centrifuged at 14,000 rpm for 1 min
at 4 1C. Subsequently, 1030 mL of supernatant was discarded. The
remainder was further agitated by vortexing for 10 min and was
fast frozen at 80 1C for 30 min. After this period, 120 mL of TE
buffer at pH 8.0 was added and used to extract the viral RNA. The
extraction of HCV RNA was performed using the QIAGEN kit,
according to the speciﬁcations of the manufacturer (QIAamp RNA
Mini Kit Hand, QIAGENs, Hilden, Germany).
2.2. Ampliﬁcation, puriﬁcation, and analysis by electrophoresis
in agarose gel
After the extraction of HCV RNA, synthesis of the cDNA of HCV
was performed, of the core and E2 region, using the enzyme
SuperScriptTM III Reverse Transcriptase (Invitrogens-Life Technol-
ogies, Carlsbad, CA, EUA) in a Mastercycler gradient thermocycler
Eppendorf (Hexasystenss S~ao Paulo, Brazil) according to manu-
facturer’s speciﬁcations, based on the methods described by
Sambrook et al. [22]. For the core region, the cDNA was ampliﬁed
by PCR with primers derived from the HCV-1b core region based on
the published nucleotide sequence 968R [23]. Primers were chosen
for ampliﬁcation product 408 pb covering a partial region of the
HCV core (amino acids 1–136), these being the sense primer VHCC
S-SR (9.14 mg/mmol) (50 cca tgg cac ata tga gca caa atc cta aac 30)
and the antisense primer (VHCC AI-SR) (8.88 mg/mmol) (50 ttg gat cct
tag tac ccc atg agg tcg gc 30) (Invitrogens-Life Technologies,
Pleasanton, CA, EUA). Restriction sites for the enzymes Nco I and
Bam HI (Fermentass-Life Sciences, Vilnius, Lithuania) were added
to the PCR product, to be subsequently cleaved and cloned into the
expression vector pET-42a in the correct orientation. For the E2
region, the cDNA was ampliﬁed by PCR using the sense primer E2.S
(10 pmol L1/mL) (50 ggc cat ggg gga aac cca cgt cac cgg 30) and the
antisense primer E2.AS (10 pmol L1/mL) (50 gct cga ggc tcg gac ctg
tcc ctg tc 30) (Invitrogens-Life Technologies, Pleasanton, CA, EUA).
The PCR product is part of the E2 protein gene (834 pb) with the
addition of restriction sites for the enzymes NcoI and XhoI (18 pb)
(Fermentass-Life Sciences, Vilnius, Lithuania) thus containing a
total of 852 pb.
The puriﬁcation of the ampliﬁed products was performed
using the kit Wizards SV Gel and PCR Clean-Up System(Promegas, Madison, WI, USA), according to manufacturer’s
speciﬁcations. Electrophoresis in agarose gel was performed for
the analysis of ampliﬁed and puriﬁed products and electrophore-
tic migration occurred at 100 V for 40 min. The gel was stained in
a solution of ethidium bromide at 0.5 mg/mL and visualized
under a transilluminator of ultraviolet (UV) light (BioRads,
Hercules, CA, USA), and the PCR product was detected as a single
fragment corresponding to the ampliﬁed region of the core
(408 bp) and the ampliﬁed region of E2 (852 bp).
2.3. Cloning and sequencing of the HCV core and E2 regions
The PCR products were cloned into the expression vector pET-
42a (Novagens, Madison, WI, USA) contained in a bacterial
inoculum of competent Escherichia coli/DH5a treated with CaCl2.
It allows the cloning and expression of the gene of interest fused
to the glutathione S-transferase (GST) protein in the N-terminal
portion of the protein (which subsequently facilitates the pur-
iﬁcation of the protein of interest) and selection with the anti-
biotic kanamycin [24]. The constructed vectors were sequenced to
conﬁrm the correct sequence and orientation of the fragments
inserted through the chain termination method of DNA sequen-
cing [25] in an automatic sequencer ‘‘MegaBACE’’ using the kit
‘‘DYEnamic ET’’ dye terminator kit (Amershams Place, Little
Chalfont, Buckinghamshire, England), according to manufacturer’s
instructions.
2.4. Enzymatic cleavage of pET-42a with inserts of the region
(core and E2) and bacterial transformation
The pET-42a with the core insert and the E2 insert were
cleaved with restriction enzymes (Nco I and Bam HI) and (NcoI
and XhoI), respectively, using the protocol provided by the
manufacturer (Fermentass—Life Sciences). Transformation took
place by using competent bacterial cells, E. coli Rosetta strain,
treated with calcium chloride (CaCl2) and 1 mL of the mini-prep
product (pET-42a with the core insert) (50 mg mL1) and pET-42a
with E2 insert (50 mg mL1) with heat shock performed for 90 s at
42 1C after which it was immediately placed on ice for 1 min. A
liquid culture medium without antibiotics was subsequently
added and incubated under agitation in a shaker at 200 rpm at
a temperature of 37 1C for 45 min. The transformed bacteria were
plated using LB agar with kanamycin (25 mg/mL) and chloram-
phenicol (25 mg mL1) (USB). After solidiﬁcation, the product of
transformation was plated and incubated at 37 1C overnight. On
the plate where the transformed bacteria were cultivated, one of
these colonies was chopped with the aid of a toothpick, inserted
into a tube containing antibiotic medium, and placed overnight
under agitation in a shaker at 250 rpm and 37 1C.
2.5. Bacterial gene expression and puriﬁcation of HCV core
and E2 recombinant proteins
Induction was performed following the methodology described
by Sambrook and Russell [26] with some modiﬁcations. First, the
bacteria E. coli Rosetta strain were transformed and plated. Then
the inoculum was prepared and grown overnight in a shaker
(Excella E24 Incubator Shaker Series, New Brunswick Scientiﬁc) at
250 rpm and 37 1C. A 1:50 dilution of this inoculum was made in
sterile LB medium (USB), with kanamycin (25 mg/mL) (USB),
chloramphenicol (25 mg/mL) (USB) and the inoculum grown over-
night and placed in an autoclaved 1 L Erlenmeyer ﬂask (to
encourage the oxygenation of the culture). The ﬂask was placed
in the shaker at 300 rpm and 37 1C until the optical density (OD) of
0.600 at 600 nm was attained, after approximately 1 h and 30 min.
It was then added to the IPTG culture (Invitrogens, Carlsbad, CA,
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induction. The culture was induced for 3 h at 37 1C in a shaker at
300 rpm. The induced culture was then centrifuged for 10 min at
5000 rpm at 4 1C (centrifuge: Sorvall High Speed Centrifuge-RC 5C
PLUS). The pellet was resuspended in a lysis buffer (100 mmol L1
NaCl, 10 mmol L1 Tris–HCl, 50 mmol L1 NaH2PO4, pH 8.0) and
thawed under manual stirring on ice until its complete dissolution.
The samples were sonicated (Sonic Dismembrator) in an ice bath for
4 min with 30 s intervals and centrifuged at 13,000 rpm for 10 min
at 4 1C. The supernatant was ﬁltered on MILLEXs HVs Durapore
PVDF Membrane of 0.45 mm. The pellet was resuspended in a lysis
buffer and stirred by vortexing for dissolution. The supernatant
was puriﬁed by column GSTrap FF (GE Healthcares Amersham
Biosciences AB SE-751 84 Uppsala, Sweden), which contains the
ligand glutathione coupled with agarose 4%. The column was
previously equilibrated with PBS and, after loading, the protein
extract was washed with ﬁve volumes of PBS and the elution buffer
(50 mmol L1 Tris–HCl, 10 mmol L1 reduced glutathione, pH 8.0)
was applied. Fractions of eluted proteins were analyzed on
SDS-PAGE 12% and stored at 20 1C until use.
2.6. Analysis of immunoreactivity of recombinant proteins
2.6.1. Western blot
Initially, to prepare the membrane that would be transferred
with the core and E2 recombinant proteins, 15 mL recombinant
core protein and 15 mL recombinant E2 protein obtained through
the puriﬁcation process by GSTrap FF column (GE Healthcares,
Amersham Biosciences AB SE-751 84 Uppsala, Sweden) were
applied in wells of polyacrylamide gel 12%. After electrophoresis,
which was performed following the method of Laemmli [27], the
proteins were transferred to a nitrocellulose membrane [28]. The
blocking of free sites on the membrane was performed with a 5%
solution of skimmed milk powder in TBS/Tween 20 (Tris
0.05 mol L1, NaCl 0.15 mol L1, pH 8.0, Tween 20 0.05%) for
18 h at 4 1C. Then the membrane was washed with TBS/Tween 20,
and pool HCV-positive serum diluted 1:400 in blocking solution
was added. Human pool HCV-negative serum was added to one of
the strips, and to assess cross-reactivity pool serum positive for
the other infectious diseases (Chagas disease, syphilis, hepatitis B,
HIV-1/2, and HTLV) diluted 1:400 in blocking solution. After 1 h
incubation at room temperature, the membrane was washed ﬁve
times with TBS/Tween 20 and incubated with anti-human IgG
conjugated with peroxidase (Sigma-Aldrichs, Saint Louis, USA),
diluted 1:10,000 in blocking solution, for 1 h at room temperature
and subsequently washed ﬁve times with TBS/Tween 20. The
revelation of the reaction was obtained by the addition of enzyme
substrates: diaminobenzidine and hydrogen peroxide (Sigma-
Aldrichs, Saint Louis, USA). After the appearance of bands, the
strips were washed once and then dried on ﬁlter paper and
photographed.2.6.2. Slot blot
Slot blot was performed in order to obtain the lowest con-
centration of reactivity of GST-core and GST-E2 proteins. The
nitrocellulose membrane Nytran (SCHLEICHER & SCHUELL-
Sigma-Aldrichs, Saint Louis, USA) was cut to an appropriate size
and equilibrated in TBS buffer (Tris 0.05 mol L1, NaCl
0.15 mol L1, pH 8.0) for 30 min. Next, the membrane was
applied in a system, Hybri SlotTM Manifold (Gibco BRL Life
Technologies-Invitrogens Carlsbad, CA, EUA) and different con-
centrations of GST protein and the recombinant core and E2
proteins puriﬁed by column GSTrap FF and serially diluted in
blocking buffer (TBS/Tween 20 and 2% BSA, starting from
50 mg mL1) were applied in a volume of 100 mL per well andthen transferred to the nitrocellulose membrane with the aid of a
vacuum pump coupled to the system. The application of vacuum
under the membrane increases the adsorption of proteins on the
membrane. After adsorption, the membrane was washed with
TBS/Tween 20 and blocked with the same solution containing 5%
BSA for 18 h at 4 1C under gentle agitation. Then the membrane
was washed ﬁve times for 5 min each with TBS/Tween 20 and
incubated with a 1:100 dilution of pool HCV-positive serum in
blocking solution. After 1 h and 30 min incubation at room
temperature, under gentle agitation, the membrane was washed
ﬁve times with TBS/Tween 20 and incubated with anti-human IgG
conjugated with peroxidase (Sigma-Aldrichs, Saint Louis, USA)
diluted 1:5000 in blocking solution for 1 h and 30 min at room
temperature under mild agitation and again washed ﬁve times
with TBS/Tween 20. The revelation of the reaction was obtained
by the addition of enzyme substrates: diaminobenzidine and
hydrogen peroxide (5 mg and 150 mL, respectively, in 30 mL PBS
pH 7.3) for 15 min at room temperature and under constant
stirring. Then the membrane was washed three times with
distilled water and dried between ﬁlter papers.
2.7. Development of diagnostic methods for HCV
2.7.1. Enzyme-linked immunosorbent assay (ELISA) via capture
The reactivity of the recombinant proteins GST-core and GST-E2
with antibodies present in the HCV-positive control serum pool
was observed on polystyrene microplates by enzyme immunoas-
say (ELISA) using the capture method developed by the Laboratory
of Immunology and Molecular Biology of the Faculty of Pharma-
ceutical Sciences (UNESP at Araraquara), with a sensitivity of 100%
and speciﬁcity of 87.5% (Master’s degree dissertation: KENFE,
2008). The polystyrene microplate was sensitized for 18 h at 4 1C
with 100 mL of monoclonal anti-GST antibody (Pharmacia
Biotechs-Sigma-Aldrichs, Saint Louis, USA) diluted 1:5000 in
carbonate/bicarbonate buffer 1 mol L1 pH 9.6. After this period,
it was washed three times with PBS-Tween 20 0.05%, blocking
solution applied (PBS pH 7.5, Tween 20 0.05%, 5% skimmed milk
powder), and the microplate incubated for 2 h at room tempera-
ture. Recombinant proteins GST-core and GST-E2 were used
together in a concentration of 5 mg mL1 each. These were
blended, homogenized, and applied well into each microplate
and incubated for 1 h at 37 1C. A 1:400 dilution of positive control
serum for HCV, antistreptolysin O (ASO), Chagas disease, syphilis,
hepatitis B, and auto-antibodies against intracellular antigens was
applied and incubated for 1 h at 37 1C. The conjugated anti-human
IgG labeled with peroxidase (Sigma-Aldrichs, Saint Louis, USA)
diluted to 1:10,000 was applied and incubated for 1 h at 37 1C. The
substrate solution of urea peroxide and tetramethylbenzidine
(Biome´rieuxs, Shanghais, China) 1:1 was applied, and after
20 min at room temperature in the absence of light sulfuric acid
(2NH2SO4) (Biome´rieuxs, Shanghais, China) 1 mol L
1 was added
to stop the reaction. The spectrophotometric reading was taken at
450 nm absorbance. Between each step, the microplate was
manually washed three times with PBS pH 7.3/Tween 20 0.05%.2.7.2. Indirect ELISA
A mixture of GST-core and GST-E2 proteins at concentrations of
2 mg mL1 of each recombinant protein was adsorbed onto the
polystyrene microplate for 18 h at 4 1C. After this period, blocking
was performed with PBS pH 7.3 and 5% skimmed milk powder and
incubation performed for 2 h at room temperature. Then the
human control serum negative and positive for HCV and positive
control serum for hepatitis B, ASO, ANA, Chagas disease, and
syphilis, and diluted 1:400 in buffer were applied and incubated
for 1 h at 37 1C. The conjugated anti-human IgG labeled with
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in blocking buffer was added and incubated for 1 h at 37 1C. The
revelation occurred using substrate solution tetramethylbenzidine
and peroxide urea 1:1, and the reaction was halted after 20 min by
adding sulfuric acid 1 mol L1. The spectrophotometric reading
was performed at a wavelength of 450 nm.
2.7.3. Development of immunoblotting
Recombinant GST-core and GST-E2 proteins adhered to the
nitrocellulose strip Millipores HF120, previously cut into 0.5 cm
pieces, applying 1.5 mL of each protein at concentrations of
24 mg mL1 and 17 mg mL1 respectively, 1.5 mL of the mixture
of the two proteins together (coreþE2) in the test zone (T) and
1.5 mL in duplicate of extracellular recombinant protein A (Sigma-
Aldrichs, Saint Louis, USA) in the concentration of 5 mg mL1 in
the control area (C) and allowed to dry for 2 h at 37 1C and then
blocked with Tris–HCl and 2% BSA for 40 min and washed three
times with Na2HPO4 and once with Tris–HCl and allowed to dry at
37 1C. After 20 h, the strips were immersed in control HCV-
positive serum diluted to 1:10 in blocking solution for 1 h and
washed with Tris–HCl and Tween 20 0.05% three times. Then the
strips were immersed in blocking solution containing anti-human
IgG antibody conjugated with peroxidase diluted to 1:300 for 1 h
and washed again. The strips were immersed in diaminobenzi-
dine substrate (5 mg) with 150 mL of H2O2 and 30 mL of PBS, and
the bands became visible in the test and control areas. The same
method was performed using HCV-negative control serum.
2.7.4. Performance veriﬁcation tests developed through the indexes
of sensitivity and speciﬁcity
The calculations of sensitivity, speciﬁcity and predictive values
were performed by applying the following formulas: Sensitivity: Values true positives/values true positivesþvalues
false negativesTable 1
Mean and standard deviation of the absorbance values obtained in the reactionSpeciﬁcity: Values true negatives/values true negativesþvalues
false positivesof capture ELISA.
Control serum 1:400 Absorbances: mean and standard deviationPositive predictive values (PPV): Values true positives/values
true positivesþvalues false positives
GST-core 5 mg mL1þGST-E2 5 mg mL1
Hepatitis C virus (HCV negative) 0.21770.027
Hepatitis C virus (HCV positive) 2.90370.050
Antistreptolysin O (ASO) 0.29770.006
Antinuclear antibodies (ANAs) 0.20970.005
Chagas disease 0.19970.008
Syphilis 0.23170.008
Hepatitis B virus 0.22670.011
Cutoff value¼0.3873.Negative predictive values (NPV): Values true negatives/values
true negativesþvalues false negatives
The serum samples were composed of pool sera from internal
control (NAC Center for Community treatment), Faculty of Phar-
maceutical Sciences UNESP/Araraquara, Brazil, and the true posi-
tive patients with hepatitis C and represent the true negative
samples from blood donors previously established as non-carriers
of hepatitis C, hepatitis B, ASO, ANA, syphilis and Chagas, all
laboratory-determined by commercial ELISA (Ortho-Clinical Diag-
nosticss) and qualitative PCR (Roches), performed according to
manufacturer’s instructions.Table 2
Mean and standard deviation of the absorbance values obtained in the reaction
of capture ELISA.
Control serum 1:400 Absorbances: mean and standard deviation
GST-core 2 mg mL1þGST-E2 2 mg mL1
Hepatitis C virus (HCV negative) 0.18370.007
Hepatitis C virus (HCV positive) 2.98670.020
Antistreptolysin O (ASO) 0.30970.011
Antinuclear antibodies (ANA) 0.18570.010
Chagas disease 0.23470.015
Syphilis 0.28070.016
Hepatitis B virus 0.28870.018
Cutoff value¼0.3873.3. Results
3.1. Expression of recombinant HCV proteins: core
and E2 fused to GST
Recombinant proteins core and E2 HCV fused to GST were
expressed in E. coli Rosetta strain with IPTG induction at a ﬁnal
concentration of 0.4 mmol L1 for 3 h at 37 1C and 300 rpm. To
conﬁrm the expression and immunoreactivity of these proteins,
immunological detection was performed by Western Blot and Slot
Blot using an HCV-positive serum pool, and the results showed
that the proteins react speciﬁcally with the HCV-positive serum
pool; when evaluated with HCV-negative control serum andHCV-positive control serum for other infectious diseases (ASO,
Chagas disease, syphilis, hepatitis B, and FAN), there was no
immunoreaction, that is, recombinant proteins reacted nonspeci-
ﬁcally (data not shown). Another fact that is equally important
and was evaluated is that protein GST alone did not react with
HCV-positive control serum or normal control serum, which
proves that the immunoreaction generated by the HCV-positive
serum pool is caused by the core and E2 recombinant proteins.3.2. Capture enzyme immunoassay
The immunoassay developed by the Laboratory of Immunol-
ogy and Molecular Biology, Faculty of Pharmaceutical Sciences,
UNESP (dissertation: KENFE, 2008), was optimized using recom-
binant HCV proteins, core and E2 together, in the concentration
5 mg mL1 each and anti-GST monoclonal antibody in the ratio
1:10,000, which afforded better immunoreactivity (Table 1).
The positive results for capture and indirect ELISA were
determined when the absorbance of the samples was above the
cutoff value, this value being the arithmetic mean of the optical
densities of negative samples (n¼12) plus two standard devia-
tions, equal to 0.3873.3.3. Indirect ELISA
This test was performed to verify an increase in immunor-
eactivity and speciﬁcity using a mixture of recombinant proteins
(GST-core and GST-E2) at concentrations of 2 mg mL1 each and
HCV-positive and HCV-negative control serum and for other
infectious and inﬂammatory diseases diluted 1:400 in blocking
buffer. This reaction is illustrated in (Table 2).
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After deﬁning the concentrations of the recombinant core and
E2 proteins of HCV, the dilution of HCV-positive and HCV-
negative control serum, and the dilution of the conjugated anti-
body, the immunoblotting assay was performed with n¼12, that
is, n¼10 for positive control serum and n¼2 for negative control
serum. As a test (T), the recombinant proteins GST-core at a
concentration of 24 mg mL1 and E2 at a concentration of
17 mg mL1 and a mixture of the two proteins (coreþE2-GST)
were applied. When negative control serum was used, there was
no reaction in the test area but only a mark in the control area.
Test results using HCV recombinant proteins can be seen in
(Fig. 1).3.5. Performance of the methods developed
Analyzing the results of tests developed and applying the results
to formulas for determining the sensitivity and speciﬁcity, the values
were 100%, for immunoblotting, because there was no test con-
ducted with the developed method that was different from the
results by commercial ELISA and PCR used for qualitative compar-
ison of the performance of the newmethod. For the developed ELISA
results were 100% sensitivity and speciﬁcity of 87.5%.4. Discussion
Since the isolation of DNA complementary to HCV by Choo
et al. [5], hepatitis C has been recognized as a major cause of
chronic liver disease worldwide; from this molecular character-
ization, many diagnostic tests have been developed. The detection
of antibodies against speciﬁc antigens of HCV is the most
common method used to identify infection, past or present. For
this screening tests are used, which have high sensitivity, and
additional tests, also called conﬁrmatory tests, are performed for
greater speciﬁcity. Due to the prevalence of infection by hepatitis C
virus, estimated at 3% of the world’s population, the diagnosis of
hepatitis C requires a very sensitive test with advantages like fast
processing, ease of automation, high reliability, and relatively
low cost.Fig. 1. Results obtained using the recombinant proteins GST-core, GST-E2 and
GST-(coreþE2), at concentration of 24 mg mL1 and 17 mg mL1, respectively.
(Strips 1–10) HCV positive control serum; row 1: (test) GST-core, 2: (test)
GST-E2, 3: (test) GST-(coreþE2), 4 and 5: (control) extracellular recombinant
protein A (Sigma-Aldrichs). (Strips 11 and 12) HCV negative control serum; row
5: (control) extracellular protein A (Sigma-Aldrichs).The detection of HCV-core protein has been useful in monitor-
ing the efﬁcacy of therapeutic protocols in subjects undergoing
hemodialysis [29–31] and in patients treated with interferon-
alpha and ribavirin [18,32]. The E2 protein is more commonly
reported in studies involving cells as it is related to different
stages of the replication cycle of HCV, having a role essential to
initiating infection, including receptor binding, fusion with the
host-cell membrane, and invasion [10,33–35].
The HCV-core protein is highly antigenic, induces speciﬁc
cellular and humoral responses, and probably plays a key role in
the pathogenesis of HCV infection [36,37], whereas the E2
glycoprotein of HCV possesses conserved areas and is responsible
for binding the virus to the target cell and the antibodies for this
region are neutralizing [38].
Considering the above, the key feature for the use of core and
E2 HCV proteins in this study was antigenicity, which assured the
speciﬁcity of the methods. These proteins expressed and fused to
GST showed no cross-reactivity in the presence of HCV-negative
serum controls and also did not show a lack of speciﬁcity
compared with control serum positive for ASO, antinuclear anti-
bodies (ANA), Chagas disease, syphilis, and hepatitis B. Moreover,
the GST protein alone produces no reactivity with HCV-positive
control serum.
The recombinant core protein is already used in some diag-
nostic tests along with the HCV proteins NS3, NS4, and NS5.
However, the use of the mixture of core and E2 recombinant
proteins fused to GST is an innovative method, as much in
immunoblotting assay as in capture and indirect enzyme immu-
noassay (ELISA). As can be seen in the immunoblotting assay, in
Fig. 1, compared with the isolated proteins there was greater
reaction intensity when core and E2 were used together, proving
to be more sensitive and speciﬁc.
Considering the above, the key feature for the use of core and
E2 proteins of HCV in this study was antigenicity, assuring the
speciﬁcity of methods.
For immunoblotting method, several steps were important for
good reproducibility of a test, as an application of reagents,
assembly and handling of nitrocellulose membrane, these proce-
dures that are performed improperly can alter the detection
limits, formats of the test and control bands, interpretation of
the results and overall performance of the test [39].
In this study, the size of the nitrocellulose strip was more
suitable than 2.5 cm long0.5 cm wide, because the test strip
with the wider, the reaction zone was higher and the performance
was not as good. In other works, the size was similar to our strips
2.5 cm long0.5 cm wide [40].
The adsorbents in the adsorption may be dispensed nitrocel-
lulose membrane in many ways either manually or by automatic
dispensers air jet speciﬁcally for this purpose, typically used at
industrial scale [41]. Our study was performed manually. The best
way of implementing the detection reagents and test control
immunoblotting HCV was the dot shape (circular) using auto-
matic pipette. Other studies have adopted this form of adsorption
of the reagents and have tracked the signal strength test and
control lines [42].
The signal on line test is related to the concentration of target
molecule in the sample is visually observed in the reaction. Other
studies correlating the staining intensity in the test line with the
concentration of the target protein and the accumulation of
conjugate in the test and control lines of the membrane [43]. In
our study some of the tests showed signal intensity line control
greater than in the line test and other tests in the staining
intensity was inversely and was also introduced equally strong
color intensity in the two lines as shown in other studies [44–46].
Test and control areas were applied 1.5 mL of adsorbent in the
reaction zone of the nitrocellulose membrane. It was reported
F.R. Kenfe et al. / Talanta 110 (2013) 32–38 37that an even smaller amount in our study, 0.5 mL for the test and
control region [40]. The average amount of adsorbent in both the
test and control areas do not exceed 2 mL because the dot this size
allows a better visualization of the signal, as described in an
article where it is applied 1–1.5 mL of the test and control
reagents [47].
The main goal of the development of an immunoassay is to
achieve maximum recognition by the antibody and/or protein.
This must have good sensitivity and reactivity of adsorbed and
then after being wetted by serological sample should not be
changed as to nature and be reactive at the time of testing. In
practice, all reagents used showed good speciﬁcity in the reac-
tions of both Western Blot, Slot Blot, ELISA and immunoblotting
and capture.
The choice of protein A standardization immunoblotting assay,
was due to its nature and it’s not enzymatic property of binding
the Fc immunoglobulin fraction [48]. It has been used for some
time to develop immunochromatographic tests, both as particle
capture conjugated to colloidal gold as the line capturing test for
antibodies in serum [49].
The immunoblotting method, we provide reliable results
regarding the procedures adopted in its development, important
for the control sera samples were used in the test application and
then compared the results obtained with other reference
methods.
During the standardization test the recombinant proteins
fused to GST and E2-HCV core used alone, together, and at
different concentrations, and the best result was obtained with
the mixture of recombinant proteins at concentrations of
24 mg mL1 and 17 mg mL1 for core and E2 respectively. To
control the area, we used the extracellular recombinant protein
A (Sigmas) at a concentration of 5 mg mL1, with excellent
results.
The performance veriﬁcation, speciﬁcity and sensitivity of the
tests was performed comparing developed serum samples or
other biological sample with classic essays employed in conven-
tional diagnosis. In our study, we found these parameters with
ELISA assays (Ortho-Clinical Diagnosticss) and qualitative PCR
(Roches) routinely performed in the laboratory of serology NAC
(core service to the community), located in the state hospital of
Ame´rico Brasilienses, Brazil.
As for the immunoreactivity of the expressed proteins fused to
GST and we can say that they did not show cross-reactivity in the
presence of serum HCV-negative controls and did not show
speciﬁcity against control sera positive for anti-streptolysin O,
antinuclear factors, wounds, syphilis, and hepatitis B. Moreover,
the GST protein alone produces no reactivity with control sera
positive for HCV. The recombinant proteins were recognized by
only anticopos anti-HCV present in control sera positive for HCV.
The ELISA assays to detect anti-HCV antibodies using recom-
binant proteins of HCV, core, and E2, so separated and mixed, this
study was designed with the purpose of comparison with the
results obtained in the test of immunoblotting, we obtained good
reactivity. We observed that the developed ELISA assays to detect
anti-core and anti-E2 was positive compared to control sera
positive for HCV and ampliﬁed with results obtained using the
mixture of recombinant proteins (coreþE2).
In the capture ELISA, the monoclonal antibody anti-GST gave
adequate guidance of the recombinant proteins fused to GST,
increasing the reactivity of anti-core and anti-E2 compared to
control serum positive for HCV, offering greater speciﬁcity and
sensitivity of the method.
Correlating the immunoblotting test for HCV developed with
the ELISA reaction and qualitative PCR showed sensitivity and
speciﬁcity of 100%, since there was no test conducted with the
developed immunoassay that was different from the resultsobtained by ELISA and commercial qualitative PCR. Tests of
indirect and capture ELISA showed 100% sensitivity and 87.5%
speciﬁcity. Why are tests developed in-house and not on an
industrial scale, the tests showed satisfactory performance com-
pared to these commercial methods.5. Conclusion
The immunoreactivity of the recombinant proteins (core and
E2) produced in a heterologous expression system (E. coli Rosetta
strain bacteria) and then puriﬁed was conﬁrmed via recognition
by anti-HCV antibodies present in hepatitis-C-positive control
serum through the techniques of Western Blot, Slot Blot, ELISA
(capture and indirect), and immunoblotting. In these trials, there
was no recognition of recombinant proteins in the presence of
control serum negative for HCV and positive for hepatitis B,
Chagas disease, syphilis, ASO, and ANA. Moreover, the GST protein
was not recognized by HCV-positive control serum, indicating its
use as a tool in viral diagnosis. The use of monoclonal anti-GST
antibody, in capture ELISA, made it possible to properly orient the
recombinant proteins fused to GST, increasing the reactivity of
anti-core and anti-E2 present in the HCV-positive serum pool.
The assay of both immunoblotting and enzyme immunoassay
(indirect and capture) using the mixture of the recombinant
proteins (coreþE2) was demonstrated to be more speciﬁc and
sensitive.
The paper showed that there is the possibility of constructing
commercial immunochromatographic test to detect anti-HCV
antibodies using recombinant proteins core-GST, GST and E2-
mixture (core-GST and E2) to a low cost because the reagents
were produced during method development sensitivity and
speciﬁcity was 100%.Acknowledgments
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